MENU
188

Innogly- COST

INNOGLY is the acronym of the COST Action CA18103: INNovation with GLYcans: new frontiers from synthesis to new biological targets.

 

The main aim of INNOGLY is to build up a multidisciplinary group of researchers to move forward new concepts, ideas and approaches to address glycan-related scientific challenges from new and wider perspectives. Specifically, the implementation of the Action rests on two pillars:

1) Glycan profiling in health and disease, where studies will be more specifically focused on glycan- based correlations in developmental and cancer biology, and glycan dependent modulation of autophagy in cancer, lysosomal disorders and neurodegenerative diseases.

2) Glycan-based diagnostics and therapeutics, where INNOGLY investigators will focus on glycan dependent fine tuning of immunity, and the exploration of the multifaceted roles of glycosaminoglycans.

 

Link:

 

- https://innogly.eu

- https://www.cost.eu/actions/CA18103/#tabs|Name:overview

 

GRANT HOLDER: Department of Chemistry ‘Ugo Schiff’, University of Firenze

Scientific Representative: Prof. Dr. Barbara Richichi

 

Leadership Positions:

 

ACTION Chair: Prof Luigi LAY

ACTION Vice Chair: Jose Juan REINA MARTIN

 

WG1: Glycan-based correlations in developmental and cancer biology. Leader: Prof. Celso REIS

WG2: Glycan dependent modulation of autophagy, endocytosis and lysosomal functions: cancer, lysosomal disorders and neurodegenerative diseases. Leader: Eeva-Liisa ESKELINEN

WG3: Glycan dependent fine tuning of immunity. Leader: Prof Barbara RICHICHI

WG4: Exploring the multifaceted roles of glycosaminoglycans (GAGs). Leader: Dr. Serge PEREZ

 

Science communication Manager: Dr. Fabrizio CHIODO

STSM coordinator: Marko ANDERLUH

 

 

Ultimo aggiornamento

10.05.2021

Cookie

I cookie di questo sito servono al suo corretto funzionamento e non raccolgono alcuna tua informazione personale. Se navighi su di esso accetti la loro presenza.  Maggiori informazioni